B. Riley Financial Reaffirms Buy Rating for Climb Bio (NASDAQ:CLYM)

Climb Bio (NASDAQ:CLYM)‘s stock had its “buy” rating restated by equities researchers at B. Riley Financial in a research report issued to clients and investors on Friday, Benzinga reports. They currently have a $30.00 price target on the stock, up from their prior price target of $26.00. B. Riley Financial’s target price indicates a potential upside of 90.94% from the company’s current price.

Other analysts have also issued research reports about the stock. B Riley reissued a “buy” rating on shares of Climb Bio in a research report on Friday. Truist Financial raised their price objective on shares of Climb Bio from $17.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Guggenheim assumed coverage on shares of Climb Bio in a report on Monday, June 8th. They set a “buy” rating and a $35.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Climb Bio in a research report on Friday, July 17th. Finally, Royal Bank Of Canada began coverage on Climb Bio in a report on Monday, August 3rd. They issued an “outperform” rating and a $23.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $25.92.

Climb Bio Price Performance

Shares of NASDAQ CLYM traded up $1.12 during trading on Friday, reaching $15.71. 949,792 shares of the stock traded hands, compared to its average volume of 991,524. The stock has a market capitalization of $902.50 million, a P/E ratio of -18.99 and a beta of 0.09. Climb Bio has a 52-week low of $1.54 and a 52-week high of $18.33. The company has a 50-day moving average of $13.99 and a 200-day moving average of $10.75.

Climb Bio (NASDAQ:CLYM) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.03. Analysts expect that Climb Bio will post -0.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Climb Bio

Several large investors have recently added to or reduced their stakes in CLYM. Legal & General Group Plc purchased a new stake in shares of Climb Bio in the 2nd quarter valued at about $45,000. XTX Topco Ltd grew its holdings in shares of Climb Bio by 19.4% during the fourth quarter. XTX Topco Ltd now owns 34,852 shares of the company’s stock worth $139,000 after purchasing an additional 5,668 shares in the last quarter. California State Teachers Retirement System bought a new position in shares of Climb Bio in the second quarter worth approximately $82,000. Virtu Financial LLC purchased a new stake in Climb Bio in the fourth quarter valued at approximately $43,000. Finally, Blair William & Co. IL purchased a new stake in Climb Bio in the fourth quarter valued at approximately $44,000. Institutional investors own 69.76% of the company’s stock.

Climb Bio News Summary

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: Promising CLYM116 clinical data: A single 320 mg dose produced a roughly 29-day half-life, near-complete APRIL suppression, and 60%–75% suppression of IgA and Gd-IgA1 through 12 weeks. The drug was generally well tolerated, with no serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia reported. Climb Bio Announces CLYM116 Phase 1 Data
• Positive Sentiment: Analyst target increases: BTIG Research raised its price target from $20 to $32 and maintained a “buy” rating. Robert W. Baird increased its target from $21 to $25 and kept an “outperform” rating. The revisions indicate that analysts see substantial upside if CLYM116 continues to demonstrate efficacy and safety.
• Positive Sentiment: Pipeline milestones remain ahead: Climb Bio expects initial data from the Phase 2 NAVIGATE-2 trial in the first half of 2027 and plans to initiate a Phase 3 study in 2027. The company’s reported dosing profile could strengthen CLYM116’s competitive position in IgA nephropathy. Oppenheimer on CLYM116 Data
• Neutral Sentiment: High volatility after a major rally: Coverage noted that CLYM had climbed approximately 1,300% over 17 months before recently pulling back. The decline appears to reflect heightened volatility and possible profit-taking rather than a newly disclosed clinical setback, but the stock remains highly sensitive to future trial results.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.